Olink Proteomics AB UPPSALA, Sweden, July 03, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK), a global leader in proteomics, introduces its inaugural network of Olink® Certified Service Providers. The group of Olink Certified Service Providers represent leading contract research organizations (CROs) and service labs around the world. Cutting-Edge Technology, Commitment to Excellence To become an Olink Certified Service Provider, each organization must undergo training, annual concordance testing, and re-certification to demonstrate their ability to consistently perform Olink workflows with the highest quality. By combining their expertise with Olink’s next-generation proteomics solutions, researchers can conveniently access this cutting-edge technology through a global network of trusted providers. “At Olink, we uphold unwavering standards of precision, reliability, and scientific excellence across all services based on our proprietary technology,” affirms Mike Irwin, Vice President, Global Sales, Support, and Marketing at Olink. “Every member of the Olink Certified Service Provider network has demonstrated exceptional proficiency in utilizing our platforms and are ready to support the global research community.” Accelerating Research, Democratizing Proteomics Olink Certified Service Providers represent an innovative ecosystem designed to accelerate scientific discovery by making access to Olink technology as simple as possible. “This network gives every scientist, regardless of their infrastructure, access to the most powerful proteomics technologies for biomarker research,” emphasizes Mike Irwin. The inaugural network of Olink Certified Service Providers is comprised of a diverse group of renowned organizations, each possessing the expertise and infrastructure to support even the most demanding research initiatives. The current members (alphabetically) include: AssayGate Australian Genome Research Facility BioXpedia CheckImmune Core Facility Metabolomics and Proteomics, Helmholtz Munich CRLB-GMEL, Hamilton Health Sciences Discovery Life Sciences Firalis Molecular Precision SA Fulgent Genetics GENEWIZ from Azenta Life Sciences Immune Assessment Laboratory, Dana-Farber Cancer Institute Immune Monitoring and Cancer Omics Labs at the OHSU Knight Cancer Institute LIFE & BRAIN LuminoDx Microcoat NBCC-HTS (Sinai Heath System) NovogeneAIT Genomics Protavio Psomagen Inc Randox Sampled Sequanta Technologies Sirona Dx Source BioScience Svar Life Science Swiss Institute of Allergy and Asthma Research Universidad CEU San Pablo, Institute of Molecular Applied Medicine Nemesio Díez (IMMA-ND) Vanderbilt University Medical Center WuXi AppTec The most up to date and complete list of Olink Certified Service Providers can be found here. Investor contact David Deuchler, CFA Gilmartin Group [email protected] Media contact Michael B. Gonzales, PhD Vice President, Global Marketing [email protected] Mobile: +1 415 308 6467 About Olink Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden. Forward-looking statements This press release contains express or implied “forward-looking statements” as defined under the Private Securities Litigation Reform Act of 1995 that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements. In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “seek,” “plan,” “outlook,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “currently, “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under the caption "Risk Factors" in our Form 20-F for the fiscal year ended December 31, 2023 (Commission file number 001-40277) and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections for the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. Olink expressly disclaims any obligation to update any forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
Olink® Introduces Global Network of Certified Service Providers to Accelerate Protein Biomarker Discovery
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...